Examination of Factors Affecting the Association of PCSK9 With Low-Density Lipoprotein Particles in Human Plasma

被引：0
|
作者：
Golder, Mia
Sarkar, Samantha
Kosenko, Tanja
McPherson, Ruth
Lagace, Thomas A.
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A433
引用
收藏
页数：2
相关论文
共 50 条
  • [31] DISCOVERY OF A NEW ROLE OF HUMAN RESISTIN IN HEPATOCYTE LOW-DENSITY LIPOPROTEIN (LDL) RECEPTOR SUPPRESSION MEDIATED BY PCSK9
    Rashid, S.
    Melone, M.
    CANADIAN JOURNAL OF CARDIOLOGY, 2011, 27 (05) : S118 - S119
  • [32] Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein (LDL) Receptor Suppression Mediated by PCSK9
    Melone, Michelle
    Rashid, Shirya
    CIRCULATION, 2011, 124 (21)
  • [33] Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation
    Rymer, Jennifer A.
    Mues, Katherine E.
    Monda, Keri L.
    Bratton, Emily W.
    Wirtz, Heidi S.
    Okerson, Ted
    Overman, Robert A.
    Brookhart, M. Alan
    Muntner, Paul
    Wang, Tracy Y.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (09):
  • [34] How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?
    Zimmerman, Marj P.
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (08): : 436 - 442
  • [35] Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model
    Dandan, Mohamad
    Han, Julia
    Mann, Sabrina
    Kim, Rachael
    Mohammed, Hussein
    Nyangau, Edna
    Hellerstein, Marc
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2021, 41 (12) : 2866 - 2876
  • [36] THE ACHIEVEMENT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGET IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE ROLE OF PCSK9 INHIBITORS
    Rizos, C.
    Athyros, V.
    Antza, C.
    Attilakos, A.
    Elisaf, M.
    Zacharis, E.
    Rallidis, L.
    Katsiki, N.
    Kiour, E., I
    Kolovou, G.
    Loulakakis, M.
    Boufidou, A.
    Skoumas, I.
    Florentin, M.
    Liberopoulos, E.
    ATHEROSCLEROSIS, 2018, 275 : E176 - E176
  • [37] Gender differences low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real world patients
    Cordero, A.
    Fernandez Del Olmo, M. R.
    Cortez Quiroga, G. A.
    Romero, C.
    Facila, L.
    Fornovi, A.
    Rondan, J.
    Bello Mora, M. C.
    Valle, A.
    Sandin, A. L. B. E. R. T.
    Freixa, R.
    Sanchez-Alvare, S.
    Blanch, P.
    Clemente Lorente, M.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2589 - 2589
  • [38] Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9
    Kamada, Yoshihiro
    Yamamoto, Akiko
    Fujiyoshi, Anna
    Koseki, Masahiro
    Morishita, Koichi
    Asuka, Tatsuya
    Takamatsu, Shinji
    Sakata, Yasushi
    Takehara, Tetsuo
    Taniguchi, Naoyuki
    Miyoshi, Eiji
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (03) : 682 - 688
  • [39] Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol
    Liu, Mi-Hua
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 195 : 212 - 214
  • [40] High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
    van Solingen, Coen
    Oldebeken, Scott R.
    Salerno, Alessandro G.
    Wanschel, Amarylis C. B. A.
    Moore, Kathryn J.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
12345